These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 22389731)

  • 21. Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences.
    Mareze VA; Borio CS; Bilen MF; Fleith R; Mirazo S; Mansur DS; Arbiza J; Lozano ME; Bruña-Romero O
    Appl Microbiol Biotechnol; 2016 Jan; 100(1):125-33. PubMed ID: 26386688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
    Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
    Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutralization of Dengue Virus Serotypes by Sera from Dengue-Infected Individuals Is Preferentially Directed to Heterologous Serotypes and Not against the Autologous Serotype Present in Acute Infection.
    Auerswald H; Kann S; Klepsch L; Hülsemann J; Rudnik I; Schreiber S; Buchy P; Schreiber M
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential heterologous neutralisation profile against strains within DENV-3 genotype II.
    Tan KK; Abubakar S
    Epidemiol Infect; 2021 Dec; 150():e33. PubMed ID: 35225194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins.
    Zidane N; Dussart P; Bremand L; Bedouelle H
    BMC Infect Dis; 2013 Jul; 13():302. PubMed ID: 23815496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.
    Andrade DV; Katzelnick LC; Widman DG; Balmaseda A; de Silva AM; Baric RS; Harris E
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.
    Uno N; Ross TM
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33208445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural strain variation and antibody neutralization of dengue serotype 3 viruses.
    Wahala WM; Donaldson EF; de Alwis R; Accavitti-Loper MA; Baric RS; de Silva AM
    PLoS Pathog; 2010 Mar; 6(3):e1000821. PubMed ID: 20333252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies.
    Gallichotte EN; Widman DG; Yount BL; Wahala WM; Durbin A; Whitehead S; Sariol CA; Crowe JE; de Silva AM; Baric RS
    mBio; 2015 Oct; 6(5):e01461-15. PubMed ID: 26463165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
    Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
    J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of tetravalent and conserved synthetic peptides vaccines derived from Dengue virus Envelope domain I and II.
    Rocha RP; Livonesi MC; Fumagalli MJ; Rodrigues NF; da Costa LC; Dos Santos MC; de Oliveira Rocha ES; Kroon EG; Malaquias LC; Coelho LF
    Virus Res; 2014 Aug; 188():122-7. PubMed ID: 24768848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation and characterization of genetically and antigenically diverse infectious clones of dengue virus serotypes 1-4.
    Tamura T; Zhang J; Madan V; Biswas A; Schwoerer MP; Cafiero TR; Heller BL; Wang W; Ploss A
    Emerg Microbes Infect; 2022 Dec; 11(1):227-239. PubMed ID: 34931940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice.
    García-Machorro J; López-González M; Barrios-Rojas O; Fernández-Pomares C; Sandoval-Montes C; Santos-Argumedo L; Villegas-Sepúlveda N; Gutiérrez-Castañeda B; Cedillo-Barrón L
    Hum Vaccin Immunother; 2013 Nov; 9(11):2326-35. PubMed ID: 23880886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The mechanism of differential neutralization of dengue serotype 3 strains by monoclonal antibody 8A1.
    Zhou Y; Austin SK; Fremont DH; Yount BL; Huynh JP; de Silva AM; Baric RS; Messer WB
    Virology; 2013 Apr; 439(1):57-64. PubMed ID: 23453578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dengue envelope-based 'four-in-one' virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice.
    Rajpoot RK; Shukla R; Arora U; Swaminathan S; Khanna N
    Sci Rep; 2018 Jun; 8(1):8643. PubMed ID: 29872153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes.
    Gallichotte EN; Baric TJ; Yount BL; Widman DG; Durbin A; Whitehead S; Baric RS; de Silva AM
    PLoS Pathog; 2018 Feb; 14(2):e1006934. PubMed ID: 29481552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.
    Messer WB; Yount BL; Royal SR; de Alwis R; Widman DG; Smith SA; Crowe JE; Pfaff JM; Kahle KM; Doranz BJ; Ibarra KD; Harris E; de Silva AM; Baric RS
    J Virol; 2016 May; 90(10):5090-5097. PubMed ID: 26962223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes.
    Bernardo L; Fleitas O; Pavón A; Hermida L; Guillén G; Guzman MG
    Clin Vaccine Immunol; 2009 Dec; 16(12):1829-31. PubMed ID: 19726617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.